Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.41 |
| ▸ | WEE1 | P30291 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827651 | 0.96 | MAPK14 (0.47) | MAPK14SYKFGFR1WEE1SRC | |
| SCHEMBL16071798 | 0.89 | FGFR1 (0.45) | MAPK14SYKFGFR1WEE1SRC | |
| SCHEMBL3536433 | 0.89 | MAPK14 (0.50) | MAPK14SYKFGFR1WEE1SRC | |
| SCHEMBL3531198 | 0.88 | MAPK14 (0.51) | MAPK14SYKFGFR1WEE1SRC | |
| SCHEMBL4024447 | 0.86 | SYK (0.56) | MAPK14SYKFGFR1WEE1SRC | |
| SCHEMBL4024442 | 0.84 | MAPK14 (0.48) | MAPK14SYKFGFR1WEE1SRC | |
| SCHEMBL3536822 | 0.84 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL3820449 | 0.81 | MAPK14 (0.66) | MAPK14 | |
| SCHEMBL5067103 | 0.81 | SRC (0.44) | MAPK14SYKFGFR1WEE1SRC | |
| SCHEMBL3534147 | 0.80 | ABL1 (0.44) | MAPK14SYKFGFR1WEE1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2094698-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008055842-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D] PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | MAP3K6, MAP3K1, MAP3K2 | MAPK14 44/4885SYK 1234/4885FGFR1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.